Background: Sentinel lymph node (SLN) status is recognized as the most important prognostic factor for patients with cutaneous melanoma. However, sometimes it is not possible to identify SLN. The phenomenon of non-identification of SLN and its prognostic role have not been thoroughly evaluated in melanoma literature. The objective of this study was to identify which patient or tumor variables may be associated to non-identification of SLN and to evaluate the prognostic role of non-identification of SLN. Methods: Observational retrospective study of 834 cutaneous melanoma patients who underwent SLN biopsy at Instituto Valenciano de Oncología. Results: Forty-two patients (5%) presented non-identification of SLN. Patients with age at diagnosis of ≥ 64 years, obesity (BMI ≥ 30), and head and neck localization were at higher risk of non-identification of SLN. Non-identified SLN patients had worse nodal disease-free survival with respect to negative SLN patients, but not worse melanoma-specific survival. Conclusions: Our findings suggest a need to follow-up patients with non-identified SLN in the same way as patients with positive SLN.
No disponible
Humans , Male , Aged , Phthirus/pathogenicity , Lice Infestations/diagnosis , Phthirus/microbiology , Phthirus/ultrastructure , Pediculus , Lice Infestations/drug therapy
Actinic cheilitis (AC) are premalignant lesions that have an increased risk of malignant transformation. Their treatment, therefore, is essential to prevent carcinogenesis. However, optimal therapy is not well established and different modalities yield variable results. Ingenol mebutate gel has recently been approved by the US Food and Drug Administration for topical treatment of actinic keratosis, with high clearance rates. On the basis of these findings, we report our experience with this drug for the treatment of AC.
Antineoplastic Agents/administration & dosage , Cheilitis/drug therapy , Diterpenes/administration & dosage , Lip Neoplasms/drug therapy , Lip/drug effects , Precancerous Conditions/drug therapy , Administration, Topical , Aged , Cheilitis/diagnosis , Gels , Humans , Lip/pathology , Lip Neoplasms/diagnosis , Male , Precancerous Conditions/diagnosis , Remission Induction , Time Factors , Treatment Outcome
Omalizumab is a monoclonal anti-IgE antibody approved for the treatment of severe allergic asthma. There is increasing evidence in the literature of its usefulness in chronic urticaria. Herein, we report a retrospective case series of 15 patients with chronic idiopathic urticaria treated with omalizumab. We reviewed their medical records to assess the improvement achieved after 3 and 6 months of treatment. Complete response was defined as symptom disappearance that could be followed by discontinuation of antihistamines, and partial response as symptom improvement, but with symptom worsening when attempting to discontinue antihistamines. After 3 months of treatment, 12 patients responded, with partial response in 9 and complete response in 3. At 6 months, 8 of 10 patients continuing on omalizumab had a complete response and 2 a partial response. The results of the present retrospective series show the effectiveness of omalizumab in most treated patients, which is consistent with other recently published series and studies. These data support its role in the management of patients with chronic urticaria refractory to conventional treatments.
Anti-Allergic Agents/therapeutic use , Antibodies, Anti-Idiotypic/therapeutic use , Antibodies, Monoclonal, Humanized/therapeutic use , Urticaria/drug therapy , Adult , Aged , Chronic Disease , Female , Humans , Male , Middle Aged , Omalizumab , Retrospective Studies
Cysts , Eccrine Glands , Paired Box Transcription Factors/metabolism , Skin Diseases , WT1 Proteins/metabolism , Adolescent , Cilia/metabolism , Cilia/pathology , Cysts/metabolism , Cysts/pathology , Diagnosis, Differential , Eccrine Glands/metabolism , Eccrine Glands/pathology , Female , Humans , PAX8 Transcription Factor , Skin Diseases/metabolism , Skin Diseases/pathology
